Department of Ophthalmology of Military Emergency Hospital "Dr. Constantin Papilian", Cluj-Napoca, 400132, Romania.
Department of Ophthalmology, "Iuliu Hatieganu" University of Medicine and Pharmacy, ClujNapoca, 400394, Romania.
Eye (Lond). 2024 Dec;38(17):3222-3230. doi: 10.1038/s41433-024-03268-x. Epub 2024 Aug 2.
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration's tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
本网络荟萃分析旨在比较不同局部非甾体抗炎药(NSAIDs)与局部皮质类固醇联合应用或不联合应用于白内障超声乳化术后预防黄斑增厚的疗效及其对视力和眼内压的影响。共检索了 5 个电子数据库,包括 PubMed、Embase、Scopus、Cochrane 图书馆和 ClinicalTrials.gov。我们的主要结局是术后 1 个月的视力结果。我们还考虑了术后 1 个月时黄斑中心凹厚度(FT)和眼内压(IOP)的变化。我们通过在随机效应模型中使用受限最大似然法计算平均值差异(MD)及其相关 95%置信区间(CI)来总结分析结果,用于连续结局。采用 Cochrane 协作工具评估研究的方法学质量。网络荟萃分析采用似然法,以 0.1%的 Nepafenac 作为参考药物。共有 11 项随机对照试验(RCT),纳入 2175 名受试者进行定量分析。术后 1 个月,Bromfenac 与 Nepafenac 0.1%相比,视力有统计学意义的改善(p<0.001),关于 FT,Nepafenac 0.3%与 Nepafenac 0.1%相比,FT 增加最少(p=0.09),关于 IOP,Diclofenac 的 IOP 最低。FT 和 IOP 方面没有显著结果。有趣的是,Ketorolac 与 BCVA 和 IOP 的结果最差,在 FT 方面排名倒数第二。总的来说,我们的网络荟萃分析表明,与 Nepafenac 0.1%相比,术后 1 个月时,Bromfenac 与视力显著改善相关,而 Nepafenac 0.3%与黄斑中心凹厚度增加最少相关。